ABBV-637
- Generic Name
- ABBV-637
Radiopharmaceutical Antibody-Drug Conjugates (rADCs) Emerge as Promising Cancer Therapies
• rADCs are designed to deliver radiation directly to cancer cells, minimizing side effects compared to traditional radiation therapy.
• Several companies are developing rADCs with various radioisotopes and antibodies, targeting cancers like prostate, breast, and lung cancer.
• Clinical trials are underway to assess the efficacy and safety of rADCs, showing promising results in reducing tumor markers like PSA.
• Challenges remain in supply chain logistics, dosimetry, and optimizing drug delivery to target tissues for effective cancer treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath